Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemvaleukin Alfa Monotherapy and in Combination with Pembrolizumab in Advanced Melanoma (ARTISTRY-6)
NCT04830124Phase 2Terminated
- Sponsor
- Mural Oncology
- Start
- Sep 2021
- Primary completion
- May 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of nemvaleukin alfa in cutaneous melanoma (CM), mucosal melanoma (MM), sponsored by Mural Oncology. Started Sep 2021; status: terminated.
02
Drugs
nemvaleukin alfa
03
Conditions
cutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04830124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830124.